Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
To reduce the number of donors treated with IV AMD3100 who require a second collection to
obtain the minimum cells necessary for allogeneic stem cell transplant.